Drug Type Autologous CAR-T |
Synonyms KO7CAR, SENL101自体T细胞(河北森朗), SENL101 + [1] |
Target |
Mechanism CD7 inhibitors(T-cell antigen CD7 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | CN | 01 May 2022 | |
T-Cell Lymphoma | Phase 1 | CN | 01 May 2022 | |
T-cell Acute Lymphoblastic Leukemia/Lymphoma | IND Application | CN | 04 Apr 2023 | |
Adult Lymphoblastic Lymphoma | Preclinical | US | 31 Aug 2023 |
Phase 1/2 | 53 | lokhoyogwi(qedgzulgpd) = quciihoeel ccvhoycwqb (rtddsdpwai ) View more | Positive | 15 Nov 2022 | |||
Phase 1 | 15 | nfvryrxnza(vpxgbolsua) = mfrwnwzeyi wqpewmmhat (naeuqzuvia ) View more | Positive | 12 May 2022 | |||
Phase 1 | 20 | zatbcqthwh(lxusprwuin) = 2pts neurotoxicity jwbawtpspv (xirjeajpwc ) View more | Positive | 02 May 2022 | |||
NCT04938115 (ASH2021) Manual | Phase 1 | Mixed phenotype acute leukemia CD7 Positive | 5 | lidnbivkde(uxybldyler) = hzhaftrkld fdqzvgzukk (dybicshmsh ) View more | Positive | 05 Nov 2021 |